According to Zacks, “Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company’s product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States. “
SRRK has been the subject of a number of other reports. Wedbush reaffirmed an “outperform” rating and set a $27.00 price objective on shares of Scholar Rock in a report on Wednesday, May 15th. ValuEngine raised shares of Scholar Rock from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.
Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.07). The firm had revenue of $5.04 million during the quarter, compared to the consensus estimate of $5.38 million. As a group, equities analysts predict that Scholar Rock will post -1.7 earnings per share for the current year.
Several large investors have recently added to or reduced their stakes in the stock. Magnetar Financial LLC acquired a new position in Scholar Rock during the second quarter valued at approximately $381,000. Susquehanna International Group LLP acquired a new position in shares of Scholar Rock during the 2nd quarter worth approximately $187,000. CVI Holdings LLC bought a new stake in shares of Scholar Rock during the 2nd quarter worth approximately $2,655,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Scholar Rock by 57.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,303,747 shares of the company’s stock valued at $20,677,000 after buying an additional 477,174 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Scholar Rock in the 2nd quarter valued at approximately $380,000. 58.52% of the stock is currently owned by institutional investors and hedge funds.
Scholar Rock Company Profile
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy.
Recommended Story: How to interpret a stock’s beta number
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.